Oragenics Stock Price, News & Analysis

Oragenics, Inc. (NYSE American: OGEN) has announced that CEO Kim Murphy will participate in the World Vaccine Congress in Washington, D.C., from April 3-6, 2023. The focus will be on the company's lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, which has shown promising safety and immunogenicity results, paving the way for upcoming Phase 1 clinical trials. Oragenics recently entered a global license agreement with Inspirevax Inc. for a novel adjuvant, BDX301, to enhance NT-CoV2-1. This intranasal vaccine aims to provide advantages over injectable vaccines, including targeting mucosal immunity.

Oragenics, Inc. (NYSE American: OGEN) has reported positive results from third-party lab tests on its lantibiotics platform, targeting antibiotic-resistant infections. The tests showed that strains of Staphylococcus aureus (MRSA) and Enterococci (VRE) remain sensitive to Oragenics' compounds, despite resistance to standard therapies. This collaboration with Linnaeus Bioscience Inc. reinforces the efficacy of lantibiotics in combating serious infections. With over 2.8 million resistant infections annually in the U.S., Oragenics is focused on meeting this need through innovative antibiotic development.

Oragenics, Inc. (NYSE American: OGEN) has appointed Janet Huffman as Chief Financial Officer, effective March 7, 2023. With over 12 years of experience in financial leadership in healthcare, Huffman's expertise in capital raising and M&A will be crucial for Oragenics' development plans. She previously served as CFO of TRxADE HEALTH and was integral in the merger of Banyan Pediatric Care Centers. Huffman aims to enhance stakeholder value through strategic financial management. Oragenics focuses on combating infectious diseases, particularly with its intranasal COVID-19 vaccine candidate, NT-CoV2-1, leveraging research from the NIH.

Oragenics, Inc. (AMEX: OGEN) has entered an exclusive global licensing agreement with Inspirevax Inc. for the development of NT-CoV2-1, its lead intranasal COVID-19 vaccine candidate, utilizing Inspirevax's BDX301 adjuvant. This partnership establishes a Joint Development Committee to oversee collaborative efforts. Oragenics will be responsible for milestone and royalty payments, with potential for future intranasal vaccine developments. The agreement aims to address unmet medical needs. In December 2022, Oragenics reported no toxicity from prior studies, suggesting a favorable safety profile for NT-CoV2-1.

Oragenics, Inc. (NYSE American: OGEN) announced that it has regained compliance with NYSE American’s continued listing standards as of February 1, 2023. The company received formal notice from NYSE American confirming that it resolved a prior deficiency related to its low stock price. The compliance indicator will no longer appear, and Oragenics is removed from the noncompliant issuers list. CEO Kimberly Murphy expressed satisfaction with the swift resolution and emphasized ongoing research and development efforts.

Oragenics, Inc. (NYSE American: OGEN) announced a 1-for-60 reverse stock split approved by its Board on December 22, 2022. The split aims to help the Company meet NYSE American's continued listing standards by increasing the market price of its shares, reducing outstanding shares from approximately 117.6 million to around 1.9 million. The split will take effect after market close on January 20, 2023, with trading of adjusted shares beginning on January 23, 2023.